# Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.

> **NCT01805557** · PHASE2,PHASE3 · COMPLETED · sponsor: **Fondazione Italiana Linfomi - ETS** · enrollment: 108 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma Refractory
- Diffuse Large B-cell Lymphoma Recurrent

## Interventions

- **DRUG:** R-DHAP
- **DRUG:** BR-DHAP

## Key facts

- **NCT ID:** NCT01805557
- **Lead sponsor:** Fondazione Italiana Linfomi - ETS
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-04
- **Primary completion:** 2019-03-12
- **Final completion:** 2020-11-20
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2022-06-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01805557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01805557, "Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01805557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*